✨ Free AI Report
Kintara Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Kintara Therapeutics, Inc.
Research Preview

Kintara Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Kintara Therapeutics, founded in 2009 and based in San Diego, is a biopharmaceutical company developing cancer therapies for patients with unmet medical needs. The company developed VAL-083, a small molecule targeting...

Analyst-debate audio for Kintara Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Kintara Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Kintara Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
3/ 10Weak

Cyborg Score thesis

Highly volatile micro-cap biotech undergoing strategic transformation with substantial downside risk and limited financial...

Read the full analyst-debate transcript →
Industry Immuno-oncology therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Kintara Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Kintara Therapeutics, Inc. Overview

Pro stress-test →

Kintara Therapeutics, founded in 2009 and based in San Diego, is a biopharmaceutical company developing cancer therapies for patients with unmet medical needs. The company developed VAL-083, a small molecule targeting DNA to inhibit cancer cell replication for treatment of ovarian cancer and metastatic breast cancer.

Strategic Profile

Pro stress-test →

Following a reverse merger with TuHURA Biosciences in October 2024, the company transformed into TuHURA Biosciences, Inc., trading under the new ticker symbol HURA on the Nasdaq Capital Market. TuHURA is a Phase 3 immuno-oncology company developing therapeutics intended to overcome resistance to cancer immunotherapy, with focus on the VISTA-inhibiting antibody TBS-2025 in blood-related cancers.

Competitive Landscape

Pro stress-test →

Kintara's top competitors include Jazz Pharmaceuticals, Moderna, and Sana Biotechnology. The company competes in the oncology sector, particularly in immuno-oncology and cancer therapeutics. Following its merger transformation, TuHURA focuses on checkpoint inhibitors and immuno-oncology, competing against larger pharma players with more established pipelines.

Industry Context

Kintara Therapeutics, Inc. operates in Immuno-oncology therapeutics.

Key facts

Founded: 2009 · Headquarters: San Diego, US · Employees: N/A · Revenue: N/A · Market cap: $163.67M (as of June 18, 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Kintara Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Kintara Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Oncology PipelineOncology and neuroscience therapeutics→Moderna TherapeuticsmRNA-based therapeutic platforms→Cell Therapy PlatformCell engineering and immunotherapy→

Compare Kintara Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kintara Therapeutics, Inc. operates in Immuno-oncology therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Immuno-oncology therapeutics research →
NEW · MCP server

Ask your AI assistant about Kintara Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kintara Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Kintara Therapeutics, Inc. do this quarter?”
“Is Kintara Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Kintara Therapeutics, Inc. do?+
Kintara Therapeutics, founded in 2009 and based in San Diego, is a biopharmaceutical company developing cancer therapies for patients with unmet medical needs. The company developed VAL-083, a small molecule targeting...
What is Kintara Therapeutics, Inc.'s Cyborg Score?+
Kintara Therapeutics, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kintara Therapeutics, Inc.'s main competitors?+
Named competitors include Oncology Pipeline, Moderna Therapeutics, Cell Therapy Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Kintara Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kintara Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kintara Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Sezzle Inc.9Carpenter Technology Corporation9Credo Technology Group Holding Ltd9TE Connectivity plc9Rheinmetall AG9Northrop Grumman Corporation9Interactive Brokers Group, Inc.9Berkshire Hathaway Inc.9Mastercard Incorporated8Vera Therapeutics, Inc.8Quoin Pharmaceuticals, Ltd.8Prenetics Global Limited8Strattec Security Corporation8Lesaka Technologies Inc.8Abu Dhabi Ship Building PJSC8Judges Scientific plc8Weathernews Inc.8Orrstown Financial Services, Inc.